➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Merck
Baxter
McKesson
Boehringer Ingelheim

Last Updated: January 19, 2021

DrugPatentWatch Database Preview

Darbepoetin alfa - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for darbepoetin alfa

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Thayyil, SudhinPhase 2
Zealand University HospitalN/A
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Phase 3

See all darbepoetin alfa clinical trials

Recent Litigation for darbepoetin alfa

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ameranth, Inc. v. Starbucks Corporation2013-05-06

See all darbepoetin alfa litigation

Pharmacology for darbepoetin alfa
Ingredient-typeErythropoietin
Physiological EffectIncreased Erythroid Cell Production

Company Disclosures: US Patents for darbepoetin alfa

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 001 2001-09-17   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2003-12-13 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 001 2001-09-17   Start Trial Amgen Inc. (Thousand Oaks, CA) 2024-05-15 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 002 2001-09-17   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2003-12-13 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 002 2001-09-17   Start Trial Amgen Inc. (Thousand Oaks, CA) 2024-05-15 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 003 2001-09-17   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2003-12-13 RX company
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 003 2001-09-17   Start Trial Amgen Inc. (Thousand Oaks, CA) 2024-05-15 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for darbepoetin alfa

These patents were identified by searching patent claims

Supplementary Protection Certificates for darbepoetin alfa

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C028/2001 Ireland   Start Trial SPC028/2001: 20031204, EXPIRES: 20160607
C0050 France   Start Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608
C/GB01/055 United Kingdom   Start Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTERED: UK EU/1/01/185/001-030 20010608
2004015 Lithuania   Start Trial PRODUCT NAME: DARBEPOETINAS ALFA (ASN30 THR32 VAL87 ASN88 THR90 EPO); REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
199059 Germany   Start Trial PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608
43/2001 Austria   Start Trial PRODUCT NAME: DARBEPOETIN-ALFA
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Merck
Dow
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.